BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 25542645)

  • 21. The NQO1 bioactivatable drug, β-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism.
    Silvers MA; Deja S; Singh N; Egnatchik RA; Sudderth J; Luo X; Beg MS; Burgess SC; DeBerardinis RJ; Boothman DA; Merritt ME
    J Biol Chem; 2017 Nov; 292(44):18203-18216. PubMed ID: 28916726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tailored Beta-Lapachone Nanomedicines for Cancer-Specific Therapy.
    Li Y; Feng M; Guo T; Wang Z; Zhao Y
    Adv Healthc Mater; 2023 Aug; 12(20):e2300349. PubMed ID: 36970948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel naphtho[2,1-d]oxazole-4,5-diones as NQO1 substrates with improved aqueous solubility: Design, synthesis, and in vivo antitumor evaluation.
    Li X; Bian J; Wang N; Qian X; Gu J; Mu T; Fan J; Yang X; Li S; Yang T; Sun H; You Q; Zhang X
    Bioorg Med Chem; 2016 Mar; 24(5):1006-13. PubMed ID: 26803578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sulindac compounds facilitate the cytotoxicity of β-lapachone by up-regulation of NAD(P)H quinone oxidoreductase in human lung cancer cells.
    Kung HN; Weng TY; Liu YL; Lu KS; Chau YP
    PLoS One; 2014; 9(2):e88122. PubMed ID: 24505400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic delivery and preclinical evaluation of Au nanoparticle containing beta-lapachone for radiosensitization.
    Jeong SY; Park SJ; Yoon SM; Jung J; Woo HN; Yi SL; Song SY; Park HJ; Kim C; Lee JS; Lee JS; Choi EK
    J Control Release; 2009 Nov; 139(3):239-45. PubMed ID: 19619590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect.
    Zhan C; Gu B; Xie C; Li J; Liu Y; Lu W
    J Control Release; 2010 Apr; 143(1):136-42. PubMed ID: 20056123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
    He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W
    Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.
    Huang X; Motea EA; Moore ZR; Yao J; Dong Y; Chakrabarti G; Kilgore JA; Silvers MA; Patidar PL; Cholka A; Fattah F; Cha Y; Anderson GG; Kusko R; Peyton M; Yan J; Xie XJ; Sarode V; Williams NS; Minna JD; Beg M; Gerber DE; Bey EA; Boothman DA
    Cancer Cell; 2016 Dec; 30(6):940-952. PubMed ID: 27960087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic Antitumor Efficacy Mediated by Liposomal Co-Delivery of Polymeric Micelles of Vinorelbine and Cisplatin in Non-Small Cell Lung Cancer.
    Wang S; Gou J; Wang Y; Tan X; Zhao L; Jin X; Tang X
    Int J Nanomedicine; 2021; 16():2357-2372. PubMed ID: 33790554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heat-induced up-regulation of NAD(P)H:quinone oxidoreductase potentiates anticancer effects of beta-lapachone.
    Park HJ; Choi EK; Choi J; Ahn KJ; Kim EJ; Ji IM; Kook YH; Ahn SD; Williams B; Griffin R; Boothman DA; Lee CK; Song CW
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8866-71. PubMed ID: 16361576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beta-lapachone suppresses radiation-induced activation of nuclear factor-kappaB.
    Dong GZ; Oh ET; Lee H; Park MT; Song CW; Park HJ
    Exp Mol Med; 2010 May; 42(5):327-34. PubMed ID: 20200474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. β-Lapachone, an NQO1 bioactivatable drug, prevents lung tumorigenesis in mice.
    Chen Y; Wu R; Li X; Cao M; Yang M; Fu B; Xuan C; Chen C; Zhou Y; Hu R
    Eur J Pharmacol; 2024 Jun; 973():176511. PubMed ID: 38604545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preparation, Characterization, and In Vivo Study of 7-Ethyl-14-Aminocamptothecin-Loaded Poly(Ethylene Glycol)2000 -Poly(Lactic Acid)2000 Polymeric Micelles Against H460 Human Nonsmall Cell Lung Carcinoma.
    Cheng X; Qiu N; Yang J; Liu H; Wen J; Wang W; Wang Z; Chen L
    J Pharm Sci; 2015 Nov; 104(11):3934-3942. PubMed ID: 26306026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lysosome-oriented, dual-stage pH-responsive polymeric micelles for β-Lapachone delivery.
    Zhou Y; Dong Y; Huang G; Wang Y; Huang X; Zhang F; Boothman DA; Gao J; Liang W
    J Mater Chem B; 2016 Dec; 4(46):7429-7440. PubMed ID: 28580145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers.
    Bey EA; Reinicke KE; Srougi MC; Varnes M; Anderson VE; Pink JJ; Li LS; Patel M; Cao L; Moore Z; Rommel A; Boatman M; Lewis C; Euhus DM; Bornmann WG; Buchsbaum DJ; Spitz DR; Gao J; Boothman DA
    Mol Cancer Ther; 2013 Oct; 12(10):2110-20. PubMed ID: 23883585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. X-ray repair cross-complementing protein 1 (XRCC1) loss promotes β-lapachone -induced apoptosis in pancreatic cancer cells.
    Zheng Y; Zhang H; Guo Y; Chen Y; Chen H; Liu Y
    BMC Cancer; 2021 Nov; 21(1):1234. PubMed ID: 34789190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis.
    Huang X; Dong Y; Bey EA; Kilgore JA; Bair JS; Li LS; Patel M; Parkinson EI; Wang Y; Williams NS; Gao J; Hergenrother PJ; Boothman DA
    Cancer Res; 2012 Jun; 72(12):3038-47. PubMed ID: 22532167
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance.
    Li X; Liu Z; Zhang A; Han C; Shen A; Jiang L; Boothman DA; Qiao J; Wang Y; Huang X; Fu YX
    Nat Commun; 2019 Jul; 10(1):3251. PubMed ID: 31324798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Self-Strengthened Oxidation-Responsive Bioactivating Prodrug Nanosystem with Sequential and Synergistically Facilitated Drug Release for Treatment of Breast Cancer.
    Wang K; Yang B; Ye H; Zhang X; Song H; Wang X; Li N; Wei L; Wang Y; Zhang H; Kan Q; He Z; Wang D; Sun J
    ACS Appl Mater Interfaces; 2019 May; 11(21):18914-18922. PubMed ID: 31055911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Susceptibility of cancer cells to beta-lapachone is enhanced by ionizing radiation.
    Park HJ; Ahn KJ; Ahn SD; Choi E; Lee SW; Williams B; Kim EJ; Griffin R; Bey EA; Bornmann WG; Gao J; Park HJ; Boothman DA; Song CW
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):212-9. PubMed ID: 15629614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.